En las noticias
Avoiding Chemo: Two Promising Drugs Go Head-to-Head in New Clinical Trial
Gateway for Cancer Research accelerates practice-changing clinical trials to cancer research by harnessing the unrelenting passion of the research community and empowering patients to triumph over their disease. All of this is guided by a clear vision: To shape a world in which a cancer diagnosis is no longer feared.
Royalty deals on the rise as Ligand takes stake in Agenus' success
Part of a growing trend in the industry, Ligand Pharmaceuticals (Nasdaq: LGND) has inked a royalty financing agreement with immunology company Agenus (Nasdaq: AGEN).
Updated Phase 1 Data Support Further Research of Botensilimab/Balstilimab in Refractory MSS CRC
Updated findings from a phase 1 trial (NCT03860272) evaluating botensilimab (AGEN1181) plus balstilimab (AGEN2034) for the treatment of patients with refractory microsatellite-stable (MSS)/mismatch repair–proficient (pMMR) metastatic colorectal cancer (mCRC) show that the combination elicited 12- and 18-month overall survival (OS) rates of 71% and 62%, respectively.
Botensilimab Combo Elicits Sustained Responses in Colorectal Cancer
Neoadjuvant botensilimab plus balstilimab appears to be safe and effective in patients with colorectal cancer regardless of mismatch repair status in the phase 2 NEST-1 trial.
New Drug Combo Shows Promising Results Against Early Stages Of Colorectal Cancer
A combination immunotherapy developed by biotech company Agenus administered before surgery destroyed over 80% of a tumor before it was removed.
Botensilimab/Balstilimab Boosts Survival in Non-MSI-H Metastatic CRC
Patients with non-microsatellite instability-high metastatic colorectal cancer had better survival rates from the botensilimab and balstilimab combination.
3 Forbes Road
Lexington, Massachusetts 02421-7305
T: +1 (781) 674 4400 | F: +1 (781) 674 4200